Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The design of this study will enable an extensive evaluation of safety, tolerability, and
PK-PD relationship following 4 weeks of dosing in patients with Coronary heart Disease